Agentix (AGTX) Common Equity (2014 - 2026)
Agentix's (AGTX) quarterly Common Equity came in at -$3.6 million in Q1 2026, down 15.83% YoY from -$4.3 million in Q1 2025, and down 2.79% on a QoQ basis from -$3.5 million in Q4 2025.
Agentix (AGTX) Common Equity (2014 - 2026) Analysis & Trends
Agentix (AGTX) has 13 years of Common Equity data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly Common Equity fell 15.83% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (down 15.83% YoY) and the FY2026 annual result came in at -$3.6 million, down 15.83% from the prior year.
- Common Equity fell to -$3.6 million in Q1 2026, from -$3.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$969834.0 in Q1 2022 to a low of -$3.6 million in Q1 2026.
- A 5-year average of -$2.6 million and a median of -$2.8 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 305.67% — and 2024, when it fell 0.76%.
- Tracing AGTX's Common Equity over 5 years: stood at -$1.9 million in 2022, then tumbled by 52.75% to -$2.8 million in 2023, then decreased by 2.49% to -$2.9 million in 2024, then fell by 19.93% to -$3.5 million in 2025, then decreased by 2.79% to -$3.6 million in 2026.
- The last three Common Equity figures came in at -$3.6 million (Q1 2026), -$3.5 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | -3.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.71 Mn |
| Mar 31, 2026 | -3.60 Mn |
| Dec 31, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.84 Mn |
| Jun 30, 2024 | -2.73 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Dec 31, 2023 | -2.85 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -2.65 Mn |
| Mar 31, 2023 | -2.25 Mn |
| Dec 31, 2022 | -1.86 Mn |
| Sep 30, 2022 | -1.62 Mn |
| Jun 30, 2022 | -1.24 Mn |
| Feb 28, 2022 | -969,834.00 |
| Nov 30, 2021 | -722,485.00 |
| Aug 31, 2021 | -555,735.00 |